Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised the underwriters on the deal. Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Tango Therapeutics on the deal while Wilson Sonsini Goodrich & Rosati represented BCTG Acquisition Corp. Tango Therapeutics announced its definitive merger agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Coridea on the deal. Coridea announced its collaboration with Deerfield Management Company, named Deerfield Device Design and Development Catalyst, to advance medtech innovation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Adicet Bio, Inc. on the deal. Adicet Bio, Inc. (Nasdaq: ACET) announced its underwritten public offering of 10,575,513 shares of its common stock,...
You must be a Standard 1 Year member to access this content.
